Blossom is an AI-native "Neopractice for Psychiatry" — a vertical marketplace that lets psychiatrists start and run their own in-network practices with an AI copilot handling documentation, prior auth, and administrative load. Product is virtual therapy plus targeted medications, delivered by independent psychiatric providers, insurance-covered, and matched to patients through a Blossom-native marketplace (Internal, Web).
Traction is genuinely elite: $21M revenue run-rate 18 months post-launch, 80% gross margin, 50% take rate, 300%+ growth since Correlation's September 2025 entry (Internal). The Series A closed at $20M in March 2026 led by Headline (Mathias Schilling on board), with Village Global, TA Ventures, Operator Partners, Correlation, and angels from General Catalyst, Flatiron, Sword Health and Fay participating (Web). StoryHouse is being invited into the Series B by Trevor Kienzle. This is a "return-on-syndicate-access" opportunity in a category where the incumbent buyer just paid $835M for Talkspace.
Telepsychiatry has been through a full boom-bust cycle: Cerebral and Done torched credibility around controlled-substance prescribing, and public players (Talkspace, Teladoc BetterHelp) failed to scale profitably. The category is now consolidating — UHS just acquired Talkspace at $835M and Spring Health acquired Alma (Web). Blossom's insurance-native, psychiatrist-run model reads as the post-Cerebral playbook, and 80% gross margin proves it works economically.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Blossom Health | AI-native "Neopractice" for psychiatry; insurance in-network; AI copilot for provider ops | $21M run-rate, 80% GM, 50% take rate; raising Series B | — |
| Talkiatry | In-network telepsychiatry across 44 states with 300+ W-2 psychiatrists | $210M raised (Feb 2026) | Blossom is later-founded, AI-native from day one, better unit economics; Talkiatry has scale advantage |
| Headway | Insurance in-network marketplace for therapists (not psychiatrists) | Series D, $2B+ valuation | Different vertical (therapy vs. medication management); Blossom owns the higher-acuity, higher-margin psychiatric slot |
| Brightside Health | DTC psychiatric care (depression/anxiety) with AI-assisted precision Rx | Series B/C | DTC vs. Blossom's provider-marketplace model — different distribution economics |
| Talkspace | Legacy virtual therapy, now scaled behavioral | Acquired by UHS at $835M (Mar 2026) | Talkspace is the exit comp, not the competitor — validates strategic-buyer appetite |
Moat: Two-sided lock-in — psychiatrists build their practice on Blossom's payer-credentialing plus AI-copilot stack, which is expensive to reproduce and creates real switching costs; the marketplace pulls patients through in-network insurance rather than paid CAC.
Obvious acquirers are hospital operators (UHS just paid $835M for Talkspace, Web), integrated payors (Elevance, UnitedHealth/Optum), and behavioral-benefit platforms (Spring Health, which itself just acquired Alma). At $21M ARR growing 300%, Blossom is on an IPO glide-path if it sustains 100%+ growth into 2027–2028; Series B pricing will determine whether the return math clears our threshold on either path.
Email intro from Trevor Kienzle at Correlation opening the Series B for Blossom. Includes company blurb and topline metrics; asks if StoryHouse is open to connecting.
Update forwarded from Correlation on their September 2025 investment: Blossom publicly announced its $20M Series A led by Headline and is on track to pass a $20M revenue run-rate — 300%+ growth since Correlation entered.